Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.35
+74.4%
$0.24
$0.17
$3.93
$1.11M-0.09130,418 shs28,638 shs
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$1.42
-21.1%
$1.87
$1.40
$16.18
$227K-0.83527,544 shs822,190 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-36.4%
$0.00
$0.00
$0.02
$772K0.9788,479 shs22,913 shs
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$3.80
+1.3%
$4.51
$2.51
$2,592.00
$163K1.51175,129 shs7,551 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-16.51%-16.41%-7.89%-30.79%-94.27%
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
+7.78%+1.69%-1.10%-23.08%+179,999,900.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-36.36%-36.36%+7.69%+40.00%-85.26%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
+2.74%-0.53%-21.88%+31.12%-99.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
2.5243 of 5 stars
0.04.00.04.62.10.01.9
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.607 of 5 stars
0.02.00.04.10.00.00.0
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$44.88M0.01N/AN/A($19.40) per share-0.07
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$23.02M0.01N/AN/A$163.50 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M$18.350.02N/AN/A-471.57%-296.50%8/7/2025 (Estimated)
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
-$2.56MN/A0.00N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
-$6.16MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.28
1.14
0.47
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
2.55%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
38160,00090,000N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
22043,000731,000Not Optionable

Recent News About These Companies

UPC’s Unexpected Plunge: What’s Next?
Universe Pharmaceuticals gets Nasdaq delisting notice
Universe Pharmaceuticals Files Registration for 37.5 Million Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.35 +0.15 (+74.39%)
As of 02:12 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Capstone Therapeutics stock logo

Capstone Therapeutics NASDAQ:CAPS

$1.42 -0.38 (-21.11%)
As of 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0014 0.00 (-36.36%)
As of 03:33 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Universe Pharmaceuticals stock logo

Universe Pharmaceuticals NYSE:UPC

$3.80 +0.05 (+1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.72 -0.07 (-1.97%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.